Today's guest is Panos Karelis, Director of Customer Experience and Insights at Intelligencia AI. Intelligencia AI is a life sciences technology company that uses proprietary data, biomedical expertise, and AI-driven algorithms to assess the probability of technical and regulatory success for drug candidates, helping pharmaceutical companies make informed decisions on which drugs to advance or discontinue. Panos joins us on today's show to explore the key challenges and opportunities in AI adoption for drug development. He discusses the "black box" problem in AI and the importance of transparency and explainability in building trust. Panos also highlights the role of high-quality, harmonized data in generating accurate AI-driven insights and the mindset shift required for organizations to integrate AI-assisted decision-making successfully. Additionally, he explains how AI can optimize clinical trial design, enhance portfolio management, and improve business development and licensing decisions. This episode is sponsored by Intelligencia AI. Learn how brands work with Emerj and other Emerj Media options at emerj.com/ad1.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related